Table 3 Comparison of FAQLQ-AF scores between oral immunotherapy patients and controls
From: Oral immunotherapy improves the quality of life of adults with food allergy
Item | Baseline | Second time point | ||||||
|---|---|---|---|---|---|---|---|---|
OIT n = 44 | Controls n = 11 | Estimate (95% CI) | p value | OIT n = 44 | Controls n = 11 | Estimate (95% CI) | p value | |
AADR | 5.5 (3.92–5.97) | 6.4 (3.50–6.60) | 0.4 (− 1.0 to 1.0) | 0.44 | 3.2 (1.50–5.60) | 5.7 (3.60–6.30) | 1.6 (0.2–3.0) | 0.02 |
EI | 5.8 (4.70–6.30) | 6.0 (4.00–6.60) | 0 (− 0.9 to 0.7) | 0.92 | 4.0 (1.92–5.40) | 6.1 (3.90–6.90) | 1.7 (0.5–3.0) | P < 0.01 |
RAE | 5.9 (3.90–5.80) | 5.6 (3.10–6.10) | 0.2 (− 0.6 to 1.2) | 0.49 | 3.3 (1.40–5.30) | 4.9 (3.80–6.50) | 1.7 (0.6–3.1) | P < 0.01 |
FAH | 3.7 (2.77–5.22) | 5.3 (4.70–6.70) | 1.4 (0.4 to 2.6) | 0.02 | 2.7 (1.70–4.92) | 4.7 (3.70–6.70) | 2.0 (0.6–3.0) | P < 0.01 |
TS | 5.2 (4.02–5.77) | 6.2 (3.70–6.40) | 0.3 (− 0.7 to 1.1) | 0.54 | 3.25 (1.60–5.10) | 5.9 (3.30–6.40) | 1.7 (0.4–3.1) | P < 0.01 |
FAIM | 4.0 (3.35–4.50) | 4.5 (2.20–5.20) | 0.3 (− 1.1 to 1) | 0.51 | 2.5 (1.85–4.20) | 4.0 (3.00–5.30) | 1.3 (0.5–2.3) | P < 0.01 |